High-plex pharmacodynamic biomarker assay
Ended Awarded Last action
- Contract number
- HHSN26100055
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $25,266,647
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $25,266,647.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $25,266,647 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute, part of the National Institutes of Health at the Department of Health and Human Services, to Leidos Biomedical Research Inc. to provide a HIGH-PLEX PHARMACODYNAMIC BIOMARKER ASSAY. The potential value of the contract is $25,266,647.00 and it does not have a set-aside designation.
Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. and has served as both a prime contractor and subcontractor for federal biomedical research efforts. For this contract, Leidos Biomedical has subcontracted with several vendors to provide specialized services and equipment, including Bio-Rad Laboratories for lab equipment maintenance, AB Sciex LLC for mass spectrometry systems, Rockland Immunochemicals Inc. for monoclonal antibody generation, and Aliz'Ee Pathology, LLC for histology services. This work supports the National Cancer Institute's broader biomedical research mission.
Quick answers
Who was awarded contract HHSN26100055?
HHSN26100055 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 21, 2017.
How much is contract HHSN26100055 worth?
The government has obligated $25,266,647 on HHSN26100055.
Is contract HHSN26100055 an order under another contract?
Yes. HHSN26100055 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100055 competed?
The extent of competition for HHSN26100055 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award